LIPO-C (LC216): a research-grade lipotropic compound for Metabolic & Liver Support
Research Use Only — LC216 (LIPO-C) is intended exclusively for in vitro and preclinical research. Not for human or veterinary consumption.
LC216 (LIPO-C) is a research-grade, multi-component lipotropic peptide formulation designed for scientific investigation into fat metabolism, mitochondrial energy transfer, hepatic lipid processing, and methylation biochemistry. Supplied as a sterile injectable solution, the LC216 peptide serves as a standardized tool for preclinical and in vitro metabolic research models.
The LC216 formulation is commonly studied in the context of body composition dynamics, lipid transport pathways, and one-carbon methylation processes — particularly in hepatic function studies, fatty acid oxidation research, and nutrient-driven metabolic shift models.
What Is the LC216 Peptide Formulation?
The LC216 peptide is a synergistic blend of lipotropic agents, amino acid derivatives, and coenzyme precursors formulated for research use. Unlike single-compound peptides, LC216 combines L-carnitine, inositol, choline, and methylcobalamin (Vitamin B12) into a single sterile solution — enabling researchers to examine the combined biochemical effects of these compounds on fat mobilization, hepatic detoxification, and energy metabolism within a single experimental variable.
Within the scientific literature, lipotropic compound blends of this nature are associated with studies on non-alcoholic fatty liver models, adipose tissue metabolism, intracellular lipid transport, and one-carbon metabolic cycling. The LC216 formulation provides a reproducible, research-grade reference for such investigations.
Key Ingredients in LC216 (LIPO-C)
- L-Carnitine — Facilitates long-chain fatty acid transport across the inner mitochondrial membrane via the CPT system; central to beta-oxidation and mitochondrial bioenergetics research.
- Inositol — Studied as a secondary messenger in insulin signaling cascades and lipid metabolism regulation; relevant to hepatic insulin sensitivity and NAFLD research models.
- Choline — Essential precursor for phosphatidylcholine and VLDL assembly; investigated in hepatic lipid export, fat mobilization, and cellular membrane integrity studies.
- Vitamin B12 (Methylcobalamin) — Bioactive coenzyme form involved in one-carbon methylation cycling, homocysteine regulation, and SAM availability; preferred over cyanocobalamin in metabolic research for superior bioavailability.
This formulation is particularly relevant for studies investigating fatty acid utilization, hepatic lipid metabolism, body composition modeling, and nutrient-driven metabolic shifts.
Biochemical Mechanism and Lipotropic Activity
Understanding how each component interacts at the cellular level is central to designing rigorous research protocols around the LC216 peptide. The following mechanisms are studied in peer-reviewed metabolic research:
Mitochondrial Fatty Acid Transport — L-Carnitine Pathway
L-carnitine facilitates the translocation of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyl transferase (CPT) system. This step is rate-limiting in beta-oxidation and is a primary focus in fat utilization and energy substrate research.
Phospholipid Synthesis and Hepatic Fat Export — Choline
Choline is an essential precursor for phosphatidylcholine, the dominant phospholipid in very-low-density lipoprotein (VLDL) assembly. Adequate choline availability is studied in the context of hepatic lipid export, preventing triglyceride accumulation in liver cell models.
Inositol Signaling and Lipid Metabolism Regulation
Inositol, particularly in its phosphoinositide forms, functions as a secondary messenger in insulin signaling cascades and lipid metabolism regulation. It is studied for its role in hepatic insulin sensitivity, cellular glucose uptake, and lipid droplet dynamics in fatty liver research models.
One-Carbon Metabolism and Methylation Cycling — Methylcobalamin
Methylcobalamin (active B12) is a coenzyme in methionine synthase reactions — a core component of the one-carbon metabolic cycle governing DNA methylation, homocysteine regulation, and SAM (S-adenosylmethionine) availability. These pathways are of interest across epigenetics, metabolic disease, and hepatic function research.
Research Applications and Study Models
The LC216 peptide has relevance across several interconnected fields of metabolic and biochemical research. Below are the primary investigative contexts where lipotropic formulations of this composition are studied:
Liver Function Studies
Lipid accumulation in hepatocytes, NAFLD/NASH models, hepatic fat export via VLDL, and detoxification pathway efficiency.
Mitochondrial Metabolism
Fatty acid beta-oxidation rates, ATP yield per substrate, carnitine shuttle kinetics, and mitochondrial membrane integrity research.
Body Composition Models
Adipose tissue dynamics, lipid mobilization efficiency, fat-free mass preservation, and substrate partitioning in caloric deficit models.
Methylation Research
One-carbon cycle regulation, DNA methylation patterns, SAM availability, and homocysteine-related cardiovascular risk biomarkers.
Nutrient-Driven Metabolic Shifts
How combined lipotropic nutrients alter lipid metabolite profiles, redox balance, and systemic energy substrate flux.
Membrane Integrity Studies
Phospholipid bilayer composition, cell membrane fluidity, and the effect of choline status on organelle membrane function.
Research-Grade LC216 from Empower Peptides
Each LC216 (LIPO-C) vial contains 20 mg/mL of actives in a 10 mL sterile aqueous solution. Empower Peptides ensures all products meet rigorous, third-party purity standards with batch-certified quality control — providing the consistency and reproducibility required for reliable research outcomes.
| Catalog Name | LC216 / LIPO-C |
| Active Concentration | 20 mg/mL |
| Solution Volume | 10 mL sterile vial |
| Formulation Type | Aqueous sterile injectable solution |
| Purity Standard | Research-grade, third-party QC tested |
| Storage | Refrigerated, protected from light |
| Intended Use | In vitro and preclinical research only |
| Regulatory Status | Not for human or veterinary use |
Frequently Asked Questions — LC216 Peptide
What makes the LC216 peptide suitable for metabolic research?
LC216 combines four biochemically complementary compounds that collectively target distinct but interconnected nodes of lipid metabolism. This makes it a useful multi-pathway tool for researchers studying synergistic lipotropic effects rather than isolating a single compound’s activity.
How does LC216 differ from single-compound carnitine or choline preparations?
Single-compound preparations isolate one mechanistic variable. The LC216 peptide blend enables researchers to study compound synergy — the interplay between carnitine-driven beta-oxidation, choline-dependent VLDL export, and B12-mediated methylation cycling — within a single experimental design.
In which research models is LC216 most commonly applied?
LC216 is studied most frequently in hepatocyte cell culture models, in vitro lipid metabolism assays, and rodent-based metabolic syndrome protocols. Its composition is also relevant to epigenetics studies focused on one-carbon metabolism and methylation cycle regulation.
What is the significance of methylcobalamin over cyanocobalamin?
Methylcobalamin is the biologically active coenzyme form of Vitamin B12 and does not require hepatic conversion before participating in methylation reactions. Research suggests it may exhibit greater bioavailability in cell-based models, making it the preferred form in formulations targeting one-carbon metabolic pathways.
Is LC216 available to research institutions?
Yes. Empower Peptides supplies the LC216 peptide to qualified research institutions and licensed investigators under rigorous quality control standards to ensure batch-to-batch consistency for reproducible experimental outcomes.
Disclaimer: LC216 (LIPO-C) is manufactured and distributed by Empower Peptides exclusively for scientific and preclinical research purposes. This product has not been evaluated by the Food and Drug Administration (FDA) or equivalent regulatory authorities. It is not intended for human consumption, is not a therapeutic drug, and must not be used as a dietary supplement. All research must be conducted by qualified investigators in compliance with applicable institutional, national, and international regulatory guidelines.
